Skip to content
Bored Studies
RecruitingPhase 4

Safety and Efficacy of iDose® TR With Cataract Surgery vs. Cataract Surgery Alone

Glaukos Corporation · NCT06848946

View Study & Apply (opens in a new tab)

Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.

Key facts

Compensation
Not posted. Ask the study team before screening.
Who can join
Ages 45+ · All sexes
Healthy volunteers
Not accepted (a condition is required)
Study type
Interventional · Phase 4
Target enrollment
132
US sites recruiting
1
Study start
January 13, 2025
Record last updated
January 21, 2026

Status re-checked against ClinicalTrials.gov within the last 12 hours.

What the study is about

This trial will evaluate the safety and IOP -lowering efficacy of administering an iDose TR (travoprost intracameral implant) in conjunction with cataract surgery compared to cataract surgery alone

Being studied: iDose TR (travoprost intracameral implant) 75 µg in conjunction with cataract surgery; Sham procedure in conjunction with cataract surgery

Conditions: Glaucoma, Open-angle; Ocular Hypertension (OHT); Phacoemulsification Cataract Surgery

Eligibility criteria

Copied from the official record. The study team makes the final decision at screening.

Show full criteria

Inclusion Criteria

  • Cataract diagnosis: clinically significant age-related cataract eligible for phacoemulsification in the study eye.
  • OAG or OHT diagnosis: either OAG (i.e. primary, pseudoexfoliation, or pigmentary glaucoma) or OHT in the study eye (i.e., eye to undergo cataract surgery)

Exclusion Criteria

  • Active corneal inflammation or edema.
  • Retinal disorders not associated with glaucoma.

Recruiting US locations

  • Glaukos Investigator Site

    Kenosha, WI 53142

    Site contact: idose@glaukos.com

Study contacts (from the official record)

  • Study Manager · 949-739-8749 · ClinicalResearch@glaukos.com
Safety and Efficacy of iDose® TR With Cataract Surgery vs.… (NCT06848946) | Bored Studies